Bronchodilator responsiveness or reversibility in asthma and COPD – a need for clarity

Igor Barjaktarevic1 Division of Pulmonary and Critical Care, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA, [email protected]Correspondence[email protected]

Robert Kaner2 Division of Pulmonary and Critical Care, Weill Cornell Medicine, NY, USA;3 Department of Genetic Medicine, Weill Cornell Medicine, NY, USA

Russell G Buhr1 Division of Pulmonary and Critical Care, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA, [email protected];4 Department of Health Policy and Management, Fielding School of Public Health at UCLA, Los Angeles, CA, USA

Christopher B Cooper1 Division of Pulmonary and Critical Care, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA, [email protected];5 Department of Physiology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA

Click to increase image sizeClick to decrease image size

Disclosure

Dr Igor Barjaktarevic reports grants from AMGEN and GE Healthcare, and personal fees from Astra Zeneca, Grifols, CSL Behring, Boehringer Ingelheim, Verona Pharama and Fisher and Paykel Healthcare, outside the submitted work. Professor Christopher Cooper reports he is employed part-time by the GlaxoSmithKline as a global medical expert with responsibilities for external scientific engagement and internal medical education. The authors report no other conflicts of interest in this work.

Bronchodilator responsiveness or reversibility in asthma and COPD – a need for clarity

Information for

Open access

Opportunities

Help and information

Bronchodilator responsiveness or reversibility in asthma and COPD – a need for clarity

Disclosure

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature